Compare · NRSN vs NVO
NRSN vs NVO
Side-by-side comparison of NeuroSense Therapeutics Ltd. (NRSN) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NRSN and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $217.28B, about 8419.9x NRSN ($25.8M).
- NRSN has been more active in the news (6 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 1 for NRSN).
- Company
- NeuroSense Therapeutics Ltd.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $25.8M
- $217.28B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 6
- 5
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NRSN
- NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"
- SEC Form 6-K filed by NeuroSense Therapeutics Ltd.
- NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
- SEC Form 6-K filed by NeuroSense Therapeutics Ltd.
- NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
- EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots
- Chief Executive Officer Ben-Noon Alon bought $200,000 worth of Ordinary Shares (250,000 units at $0.80), increasing direct ownership by 6% to 4,534,233 units (SEC Form 4)
- Chief Financial Officer Eisenberg Or bought $200,000 worth of Ordinary Shares (250,000 units at $0.80), increasing direct ownership by 20% to 1,504,050 units (SEC Form 4)
- NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS
- SEC Form 6-K filed by NeuroSense Therapeutics Ltd.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S